ILB® has highly specific properties that address the underlying pathology to activate repair and protection.

Science with a new approach

ILB’s mechanism of action may either reduce the triggers that lead to cell death or prevent further pathology even if triggers are present. By addressing the underlying processes of disease, ILB could significantly improve outcomes for people suffering from otherwise untreatable progressive and disabling conditions.

  • Broad applicability in acute and neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS) and stroke plus traumatic brain injury and glaucoma.

  • Addresses the underlying pathology of the diseases, enabling self-repair instead of just treating the symptoms.

  • Subcutaneous dosing simplifies administration for the patient and makes it suitable for longer term treatment.


Activates MMPs and blocks pro-fibrotic TGF-β.

Increases glutamate uptake.

Pro-angiogenic and attenuates angiopathies.

Normalizes mitochondrial function.

Attenuates microglial activation.

Blocks β-amyloid oligomerisation and plaque formation.

Stabilizes neurofilaments and enhances growth factor transport.

Pipeline for ILB

Clinical Phase I
Clinical Phase IIA
Clinical Phase IIB
Phase III
Phase IV

Development phases

ILB has a solid set of non-clinical and clinical data covering a broad range of indications. These will be used as a basis for CRO-monitored clinical trials.

For more information, please refer to

Completed clinical studies

Study 1

20 subjects were dosed once. ILB was found to be safe and well-tolerated when administered as an intravenous bolus dose of 1.5 mg/kg followed by a 20-min infusion of 3.0 mg/kg and 5-h infusion of up to ~ 9 mg/kg. A minor AE and no SAEs were recorded.

Study 2

24 subjects were dosed once intravenously ranging from 3 to 24 mg/kg. ILB was found safe and well-tolerated in all administered doses. There were minor AEs reported and no SAEs.

Study 3

Crossover intravenous and subcutaneous dosing was administered to 12 healthy volunteers. No SAEs or withdrawals were recorded. Mild bruising around the injection site was noted up to 24 h after injection. No hypersensitivity reactions were recorded. Subcutaneous dosing was found suitable for future administration. Mean absolute bioavailability was 94%.

Planned clinical studies

Several CRO-monitored Phase II studies in different indications are being evaluated.